[{"id":"c9fa59c0-ee9b-4c5f-baf7-8f04f47fe653","acronym":"","url":"https://clinicaltrials.gov/study/NCT05630794","created_at":"2022-11-30T18:57:52.049Z","updated_at":"2025-02-25T13:41:21.187Z","phase":"Phase 1","brief_title":"Testing ONC201 to Prevent Colorectal Cancer","source_id_and_acronym":"NCT05630794","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • IL6 • TNFA • IL10 • CASP3 • GZMA • IL17A • PRL","pipe":"","alterations":" ","tags":["BCL2 • IL6 • TNFA • IL10 • CASP3 • GZMA • IL17A • PRL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Modeyso (dordaviprone)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 03/30/2025","start_date":" 03/30/2025","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2025-02-21"},{"id":"5a5cc7eb-02a2-447b-b845-f09f374e981c","acronym":"","url":"https://clinicaltrials.gov/study/NCT06832982","created_at":"2025-02-25T12:31:42.539Z","updated_at":"2025-02-25T12:31:42.539Z","phase":"Phase 1","brief_title":"Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002","source_id_and_acronym":"NCT06832982","lead_sponsor":"Shanghai Pushi Medical Science Co. Ltd","biomarkers":" IFNG • IL10","pipe":"","alterations":" ","tags":["IFNG • IL10"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 86","initiation":"Initiation: 02/13/2025","start_date":" 02/13/2025","primary_txt":" Primary completion: 09/26/2025","primary_completion_date":" 09/26/2025","study_txt":" Completion: 09/26/2026","study_completion_date":" 09/26/2026","last_update_posted":"2025-02-18"},{"id":"95346b3d-9ef2-4e77-bfd1-0fdc5d0b84e5","acronym":"","url":"https://clinicaltrials.gov/study/NCT06707259","created_at":"2025-02-25T16:41:47.922Z","updated_at":"2025-02-25T16:41:47.922Z","phase":"Phase 1","brief_title":"Clinical Study of Cord Blood-derived IL-10 CD19-CAR NK in the Treatment of Refractory/Relapsed B-cell NHL","source_id_and_acronym":"NCT06707259","lead_sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","biomarkers":" IL10","pipe":"","alterations":" ","tags":["IL10"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 12/01/2024","start_date":" 12/01/2024","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-06"},{"id":"c18480ea-e56b-4074-80ac-afaf290dce63","acronym":"","url":"https://clinicaltrials.gov/study/NCT04556045","created_at":"2021-01-18T21:46:44.852Z","updated_at":"2025-02-25T16:53:16.785Z","phase":"","brief_title":"Exercise Therapy and Radiation Therapy (EXERT) for Metastatic Prostate Cancer","source_id_and_acronym":"NCT04556045","lead_sponsor":"Case Comprehensive Cancer Center","biomarkers":" IL6 • TNFA • CXCL8 • IL10 • IL15 • IL1B","pipe":"","alterations":" ","tags":["IL6 • TNFA • CXCL8 • IL10 • IL15 • IL1B"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 12/11/2023","start_date":" 12/11/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-02-04"},{"id":"80d5522f-7e62-4840-9814-99046b8adfc5","acronym":"DEKA-1","url":"https://clinicaltrials.gov/study/NCT05704985","created_at":"2023-01-30T15:59:33.980Z","updated_at":"2025-02-25T17:31:52.518Z","phase":"Phase 1","brief_title":"Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors","source_id_and_acronym":"NCT05704985 - DEKA-1","lead_sponsor":"DEKA Biosciences","biomarkers":" EGFR • IL2 • IL10","pipe":" | ","alterations":" EGFR expression","tags":["EGFR • IL2 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • carboplatin • paclitaxel • 5-fluorouracil • capecitabine • oxaliplatin • DK210 (EGFR)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 04/03/2023","start_date":" 04/03/2023","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2025-01-23"},{"id":"2e87885c-4e7c-4eee-af7f-c60a1af4ea15","acronym":"SPIRAL","url":"https://clinicaltrials.gov/study/NCT06785974","created_at":"2025-02-25T19:12:33.814Z","updated_at":"2025-02-25T19:12:33.814Z","phase":"Phase 4","brief_title":"Statins to Prevent Immune Checkpoint Inhibitor-induced PRogression of AtherosLerosis","source_id_and_acronym":"NCT06785974 - SPIRAL","lead_sponsor":"Erasmus Medical Center","biomarkers":" IL6 • TNFA • IL10 • IL1B • CRP","pipe":"","alterations":" ","tags":["IL6 • TNFA • IL10 • IL1B • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e atorvastatin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 02/01/2025","start_date":" 02/01/2025","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2030","study_completion_date":" 02/01/2030","last_update_posted":"2025-01-22"},{"id":"a78706c6-c75a-4948-a72e-5e293212da18","acronym":"","url":"https://clinicaltrials.gov/study/NCT03626220","created_at":"2025-02-25T19:10:33.948Z","updated_at":"2025-02-25T19:10:33.948Z","phase":"","brief_title":"Acupuncture on Chemotherapy-induced Peripheral Neuropathy","source_id_and_acronym":"NCT03626220","lead_sponsor":"China Medical University Hospital","biomarkers":" TNFA • IL10","pipe":"","alterations":" ","tags":["TNFA • IL10"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 06/27/2018","start_date":" 06/27/2018","primary_txt":" Primary completion: 10/10/2020","primary_completion_date":" 10/10/2020","study_txt":" Completion: 10/10/2020","study_completion_date":" 10/10/2020","last_update_posted":"2025-01-20"},{"id":"08da958b-deab-46fd-9448-9e7d0dc1d817","acronym":"KEYNOTE B84","url":"https://clinicaltrials.gov/study/NCT04815720","created_at":"2021-03-25T11:52:15.829Z","updated_at":"2025-02-25T16:11:18.429Z","phase":"Phase 1/2","brief_title":"Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","source_id_and_acronym":"NCT04815720 - KEYNOTE B84","lead_sponsor":"Vaccinex Inc.","biomarkers":" PD-L1 • IFNG • IL6 • TNFA • CD4 • IL2 • IL10 • TGFB1","pipe":"","alterations":" ","tags":["PD-L1 • IFNG • IL6 • TNFA • CD4 • IL2 • IL10 • TGFB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • pepinemab (VX15)"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 08/09/2021","start_date":" 08/09/2021","primary_txt":" Primary completion: 07/24/2024","primary_completion_date":" 07/24/2024","study_txt":" Completion: 07/24/2024","study_completion_date":" 07/24/2024","last_update_posted":"2025-01-08"},{"id":"29969cfe-2b37-4195-9895-8e10c1f2fc4d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06482905","created_at":"2025-02-26T07:12:20.689Z","updated_at":"2025-02-26T07:12:20.689Z","phase":"Phase 1","brief_title":"Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.","source_id_and_acronym":"NCT06482905","lead_sponsor":"Tcelltech Inc.","biomarkers":" IFNG • IL6 • TNFA • IL2 • IL10","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • IL2 • IL10"],"overall_status":"Recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 09/04/2024","start_date":" 09/04/2024","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-01-08"},{"id":"b3d0abdf-0279-4d36-aa6d-69fe2e62ba80","acronym":"SHR-1316-SCLC-LN-001","url":"https://clinicaltrials.gov/study/NCT06480864","created_at":"2025-02-26T07:35:04.037Z","updated_at":"2025-02-26T07:35:04.037Z","phase":"","brief_title":"Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer","source_id_and_acronym":"NCT06480864 - SHR-1316-SCLC-LN-001","lead_sponsor":"Yunpeng Liu","biomarkers":" PD-L1 • IL6 • IL10","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • IL6 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • AiTan (rivoceranib) • etoposide IV • AiRuiLi (adebrelimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 08/09/2024","start_date":" 08/09/2024","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2025-01-06"},{"id":"e083e3f6-9297-475c-8844-e43c062a3d0a","acronym":"DAANCE","url":"https://clinicaltrials.gov/study/NCT06749210","created_at":"2025-02-26T07:40:40.489Z","updated_at":"2025-02-26T07:40:40.489Z","phase":"Phase 2","brief_title":"DAANCE FOR CHEMOTHERAPY-INDUCED NEUROPATHY","source_id_and_acronym":"NCT06749210 - DAANCE","lead_sponsor":"Ohio State University Comprehensive Cancer Center","biomarkers":" IL6 • TNFA • IL10 • BDNF • GFAP","pipe":"","alterations":" ","tags":["IL6 • TNFA • IL10 • BDNF • GFAP"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 01/01/2025","start_date":" 01/01/2025","primary_txt":" Primary completion: 09/01/2030","primary_completion_date":" 09/01/2030","study_txt":" Completion: 09/01/2030","study_completion_date":" 09/01/2030","last_update_posted":"2025-01-06"},{"id":"84edb0cb-23b4-41c9-a4af-3815707a7019","acronym":"","url":"https://clinicaltrials.gov/study/NCT05958719","created_at":"2025-02-26T07:45:46.896Z","updated_at":"2025-02-26T07:45:46.896Z","phase":"Phase 2","brief_title":"Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma","source_id_and_acronym":"NCT05958719","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital, China","biomarkers":" IFNG • IL6 • TNFA • IL10 • IFNA1","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • IL10 • IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • prednisone • Epidaza (chidamide) • Duoenda (mitoxantrone liposomal)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 03/02/2023","start_date":" 03/02/2023","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 03/02/2027","study_completion_date":" 03/02/2027","last_update_posted":"2024-12-30"},{"id":"56e2e82d-0917-4545-b455-4c16a9d9c3bb","acronym":"CMD03","url":"https://clinicaltrials.gov/study/NCT06612645","created_at":"2025-02-26T10:08:23.382Z","updated_at":"2025-02-26T10:08:23.382Z","phase":"Phase 1","brief_title":"Safety and Efficacy of CMD03 CAR T Cell in Children With Relapse or Refractory Solid Tumors","source_id_and_acronym":"NCT06612645 - CMD03","lead_sponsor":"Chulalongkorn University","biomarkers":" IFNG • IL6 • CD276 • TNFA • IL2 • IL7R • IL10","pipe":"","alterations":" ","tags":["IFNG • IL6 • CD276 • TNFA • IL2 • IL7R • IL10"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 12/01/2024","start_date":" 12/01/2024","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-12-09"},{"id":"949b2ac3-8269-489d-a405-99b472b2028a","acronym":"CA209-6D9","url":"https://clinicaltrials.gov/study/NCT05704933","created_at":"2023-01-30T15:59:33.242Z","updated_at":"2025-02-25T14:17:35.071Z","phase":"Phase 1","brief_title":"Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases","source_id_and_acronym":"NCT05704933 - CA209-6D9","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" CD8 • PD-1 • IFNG • CD4 • IL2 • IL10","pipe":" | ","alterations":" PD-1 expression","tags":["CD8 • PD-1 • IFNG • CD4 • IL2 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 06/06/2023","start_date":" 06/06/2023","primary_txt":" Primary completion: 06/07/2024","primary_completion_date":" 06/07/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-12-09"},{"id":"06d6d872-b4db-4722-a986-805b221dc90d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06599619","created_at":"2025-02-26T07:20:01.996Z","updated_at":"2025-02-26T07:20:01.996Z","phase":"","brief_title":"Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi","source_id_and_acronym":"NCT06599619","lead_sponsor":"John Kirkwood","biomarkers":" BRAF • CD8 • PD-1 • IL6 • IL10 • SOX10","pipe":"","alterations":" ","tags":["BRAF • CD8 • PD-1 • IL6 • IL10 • SOX10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/01/2024","start_date":" 11/01/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-11-06"},{"id":"da8385f8-d966-4338-afb8-29be3c58c4e6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05650827","created_at":"2025-03-03T11:24:03.773Z","updated_at":"2025-03-03T11:24:03.773Z","phase":"","brief_title":"Feasibility and Effect of Resistance Training and Protein Supplementation in Patients With Advanced Gastroesophageal Cancer","source_id_and_acronym":"NCT05650827","lead_sponsor":"Rigshospitalet, Denmark","biomarkers":" IFNG • IL6 • TNFA • IL10 • CRP","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • IL10 • CRP"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 02/24/2023","start_date":" 02/24/2023","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-11-05"},{"id":"a062c74c-382b-45ce-ae14-0fed8ad9e6f5","acronym":"","url":"https://clinicaltrials.gov/study/NCT06666881","created_at":"2025-02-26T15:17:28.737Z","updated_at":"2025-02-26T15:17:28.737Z","phase":"","brief_title":"Skeletal Muscle Mass Changes on Images for Prediction of Prognosis After Exercise Training in HNSCC Patients","source_id_and_acronym":"NCT06666881","lead_sponsor":"Chang Gung Memorial Hospital","biomarkers":" IL10 • IL15 • IL1B","pipe":"","alterations":" ","tags":["IL10 • IL15 • IL1B"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 06/06/2023","start_date":" 06/06/2023","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2024-10-31"},{"id":"2d9a8f08-c565-475d-9d28-781aa1dd5529","acronym":"","url":"https://clinicaltrials.gov/study/NCT06662006","created_at":"2025-02-26T07:54:41.562Z","updated_at":"2025-02-26T07:54:41.562Z","phase":"Phase 2","brief_title":"Nal-IRI/5-FU/LV Chemotherapy Combined with PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT As Second-line Therapy in Metastatic Pancreatic Cancer Patients","source_id_and_acronym":"NCT06662006","lead_sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","biomarkers":" IFNG • IL6 • TNFA • IL2 • IL10 • IL17A • IFNA1 • IL1B","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • IL2 • IL10 • IL17A • IFNA1 • IL1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • Focus V (anlotinib) • Andewei (benmelstobart) • Onivyde (nanoliposomal irinotecan)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 10/01/2024","start_date":" 10/01/2024","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-10-28"},{"id":"9b80d640-ac33-4411-ad4d-9614359a1e32","acronym":"","url":"https://clinicaltrials.gov/study/NCT02265536","created_at":"2025-07-19T14:00:09.317Z","updated_at":"2025-07-19T14:00:09.317Z","phase":"Phase 1","brief_title":"A Study of LY3022855 In Participants With Breast or Prostate Cancer","source_id_and_acronym":"NCT02265536","lead_sponsor":"Eli Lilly and Company","biomarkers":" CD8 • PD-1 • IFNG • IL6 • LAG3 • TNFA • CTLA4 • IL2 • ICOS • IL10 • CD14 • FOXP3 • IL1B","pipe":"","alterations":" ","tags":["CD8 • PD-1 • IFNG • IL6 • LAG3 • TNFA • CTLA4 • IL2 • ICOS • IL10 • CD14 • FOXP3 • IL1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LY3022855"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 11/03/2017","primary_completion_date":" 11/03/2017","study_txt":" Completion: 11/03/2017","study_completion_date":" 11/03/2017","last_update_posted":"2024-10-28"},{"id":"e6348fae-b8af-4208-b102-e5ec338c0f08","acronym":"","url":"https://clinicaltrials.gov/study/NCT06660056","created_at":"2025-02-26T15:15:08.815Z","updated_at":"2025-02-26T15:15:08.815Z","phase":"Phase 1","brief_title":"A Phase I Clinical Study of Intratumoral Injection GC001 in Patient With Recurrent or Progressive Gliomas","source_id_and_acronym":"NCT06660056","lead_sponsor":"GONGCHU Biotechnology Co., Ltd","biomarkers":" PD-1 • IFNG • IL6 • TNFA • CD4 • IL10","pipe":"","alterations":" ","tags":["PD-1 • IFNG • IL6 • TNFA • CD4 • IL10"],"overall_status":"Recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 10/08/2024","start_date":" 10/08/2024","primary_txt":" Primary completion: 02/08/2026","primary_completion_date":" 02/08/2026","study_txt":" Completion: 08/08/2026","study_completion_date":" 08/08/2026","last_update_posted":"2024-10-26"},{"id":"fba341c7-84e9-4879-bf38-162dc489e17a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03858153","created_at":"2025-07-19T14:17:17.932Z","updated_at":"2025-07-19T14:17:17.932Z","phase":"Phase 2","brief_title":"Exercise and Nutrition Interventions During Chemotherapy K07","source_id_and_acronym":"NCT03858153","lead_sponsor":"University of Rochester","biomarkers":" IL6 • IL10","pipe":"","alterations":" ","tags":["IL6 • IL10"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 04/15/2019","start_date":" 04/15/2019","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 08/31/2025","study_completion_date":" 08/31/2025","last_update_posted":"2024-10-11"},{"id":"fab7c1a5-865b-44d1-9464-2b668a7a8d95","acronym":"","url":"https://clinicaltrials.gov/study/NCT06626633","created_at":"2025-02-26T15:02:37.996Z","updated_at":"2025-02-26T15:02:37.996Z","phase":"Phase 1","brief_title":"2321GCCC: CRD3874-SI in Patients with Relapsed/refractory AML","source_id_and_acronym":"NCT06626633","lead_sponsor":"University of Maryland, Baltimore","biomarkers":" IFNG • TNFA • IL10 • STAT6 • IFI27 • IFNA1 • IL1B • NFKB2 • IRF7 • JUNB","pipe":"","alterations":" ","tags":["IFNG • TNFA • IL10 • STAT6 • IFI27 • IFNA1 • IL1B • NFKB2 • IRF7 • JUNB"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 08/26/2024","start_date":" 08/26/2024","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/31/2028","study_completion_date":" 01/31/2028","last_update_posted":"2024-10-04"},{"id":"3385c8c2-d2a8-4dfb-904b-d2b81538ee4e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06599710","created_at":"2025-02-26T14:44:18.610Z","updated_at":"2025-02-26T14:44:18.610Z","phase":"","brief_title":"The Effects of a Food Product Containing Mushroom Extracts (AndoSanTM) in Subjects with Colorectal Cancer-related Fatigue","source_id_and_acronym":"NCT06599710","lead_sponsor":"Mycotech Pharma AS","biomarkers":" IL6 • TNFA • IL10 • IL17A","pipe":"","alterations":" ","tags":["IL6 • TNFA • IL10 • IL17A"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/09/2024","start_date":" 09/09/2024","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-09-20"},{"id":"c9ecae37-5dfc-4f0d-a35f-98cf8dfd80f5","acronym":"","url":"https://clinicaltrials.gov/study/NCT06603519","created_at":"2025-02-27T08:28:24.813Z","updated_at":"2025-02-27T08:28:24.813Z","phase":"","brief_title":"Impact of Dietary Intervention on Inflammation and Microbiome Composition Post-Colonoscopy","source_id_and_acronym":"NCT06603519","lead_sponsor":"University of California, San Diego","biomarkers":" IL6 • IL10","pipe":"","alterations":" ","tags":["IL6 • IL10"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/30/2024","start_date":" 09/30/2024","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-09-19"}]